Open AccessAntiretroviral Therapy–Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial
Author(s) -
Ighovwerha Ofotokun,
Lauren F Collins,
Kehmia Titanji,
Antonina G. Foster,
Caitlin A. Moran,
Anandi N. Sheth,
Cecile Delille Lahiri,
Jeffrey L. Lennox,
Laura Ward,
Kirk A. Easley,
M. Neale Weitzmann
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz1027
Subject(s) - medicine , placebo , zoledronic acid , n terminal telopeptide , bone resorption , bone remodeling , bone mineral , osteoporosis , femoral neck , urology , clinical endpoint , gastroenterology , randomized controlled trial , surgery , pathology , alkaline phosphatase , biochemistry , chemistry , alternative medicine , osteocalcin , enzyme
Human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) are associated with bone loss leading to increased fracture rate among persons with HIV (PWH). We previously showed long-acting antiresorptive zoledronic acid (ZOL) prevented ART-induced bone loss through 48 weeks of therapy and here investigate whether protection persisted.